WHO vaccine-preventable diseases: monitoring system. 2017 global summary

Last updated 06-Sep-2017 (data as of 05-Sep-2017)
Next overall update 2018
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 13'3901 Infant (under 12 months) mortality rate: 62
GDP / capita (US$): 22'9681 Child (under 5 years) mortality rate: 82

Population data in thousands3

  2016  2015  2014  2013  2012  2000  1990  1980 
Total population 101  100  99  98  97  84  67  73 
Births
Surviving infants
Pop. less than 5 years
Pop. less than 15 years 24  25  25  25  25  25  21  26 
Female 15-49 years 28  28  28  28  28  25  18  19 

Number of reported cases

(Click for retrospective incidence data for Antigua and Barbuda)
Diphtheria
ChartChart
 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  2'291 
Mumps
ChartChart
 
Pertussis
ChartChart
 
Polio*
ChartChart
 
Rubella
ChartChart
 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
 
Tetanus (total)**
ChartChart
 
Yellow fever
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Antigua and Barbuda)
Vaccine year result method % card seen                                                
BCG          99 
DTP1          88  99*  99*  98  90 
DTP3          92  99*  99*  99  98  95  99  54 
DTP4          99 
IPV1          21 
HepB_BD         
HepB3          92  99*  99*  98  98 
Hib3          92  99*  99*  99  98 
JapEnc         
MCV1          88  99*  99*  99*  98  95  89 
MCV2          68  99*  87  90 
MenA         
PCV1         
PCV2         
PCV3         
Pol3          87  86  96  98  97  96  99  36 
Rota1         
RotaC         
RCV1          88  99*  99*  99* 
TT2plus         
PAB         
VAD1         
YFV         
* indicates the country reported above 100% coverage.

  Next update: Mid-July 2018

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Antigua and Barbuda)
DTP1
ChartChart
  99  99  99  99  99  98  99  77 
DTP3
ChartChart
  99  99  99  99  98  95  99  54 
HepB3
ChartChart
  99  99  99  99  98 
HepB_BD
ChartChart
 
Hib3
ChartChart
  99  99  99  99  98 
MCV1
ChartChart
  98  98  98  98  98  95  89 
MCV2
ChartChart
  87  87  87  87  90 
PCV3
 
Pol3
ChartChart
  86  86  96  98  97  96  99  36 
RCV1
ChartChart
  98  98  98  98  98  95  89 
RotaC
 

Click for WHO-UNICEF coverage estimates data for PAB time series.

Number of districts in the country Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 75
From 80 to 89% 13
From 50 to 79% 13
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2016 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
DT 4-5 years; Yes
DTwP 18 months; Yes
DTwPHibHepB 2, 4, 6 months; Yes
HepB_Adult 1st contact; +1 +6 months; Yes
HepB_Pediatric 1st contact; +1 +6 months; Yes
HPV 9 years; +6 months; Yes From 2018
Influenza_Adult >=35 months; Yes
Influenza_Pediatric 6-35 months; Yes
IPV 2, 4 months; Yes
MMR 12, 18 months; Yes
OPV 2, 4, 6, 18 months; 4-5 years; Yes
Pneumo_conj 2, 4, 6 months; No risk groups
Pneumo_ps 1st contact No risk groups
Td 1st contact; + 4 weeks; +6 months; Yes and at 15 years
Varicella 3-5 years; No volontary
YF 1st contact; Yes travelers to endemic countries

Immunizaton indicators

Indicator Expected answer 2016  2015  2014  2013  2012  2011  2010 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No    No    No  No  No 
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number            

System performance

Total Nº districts in country number 34   
Nº districts with DTP3 coverage >=80% number 15  14 
% of districts with DTP3 coverage >=80% From 0 to 100% 88  88  44    100  100  100 
Nº districts with measles (MCV1) coverage >=95% number 13 
% of districts with MCV1 coverage >=95% From 0 to 100% 38  75  38    100  100  100 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  Yes  Yes    Yes  Yes  No 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes    Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%   100      93  EC$90,470.62   

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR No  No  No    No  No  No 

Sources

 1  "The 2017 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2016, data for 2015
 3  "United Nations, Population Division. The World Population Prospects - the 2017 revision". New York, 2017.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.